Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Tiny Boston biotech Pieris nabs $570M+ cancer deal with French powerhouse Servier, validating the Anticalin platform with a marquee European partner.
Servier and Pieris launch up to EUR 1.7B immuno-oncology alliance for five bispecific Anticalin therapeutics, with PRS-332 as the lead…
Pieris loses Servier as partner for cancer immunotherapies after Servier exits the 2017 Anticalin alliance citing a potential safety signal in the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Servier and Pieris launched a strategic immuno-oncology co-development alliance for five bispecific Anticalin therapeutics led by PRS-332 (anti-PD-1 Anticalin bispecific). Servier paid Pieris EUR 30M (~$31M) upfront plus eligibility for up to EUR 324M (~$338M) in milestones for PRS-332 and up to EUR 193M per additional program (~EUR 1.5B / ~$1.7B aggregate) plus tiered royalties. Pieris retains U.S. commercial rights; Servier holds ex-U.S. rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Pieris Pharmaceuticals, Inc. (this deal) | 2017 | $1.7B | — |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Symphogen A/S | 2020 | — | — |
| Servier / IDEAYA Biosciences, Inc. | 2025 | $530M | — |
← Browse all deals · How we score deals
More: 2017 deals · Servier deals · Oncology deals